comparemela.com

Latest Breaking News On - Ed arce - Page 4 : comparemela.com

AcelRx Pharmaceuticals, Inc (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript

Operator: Welcome to the AcelRx third quarter 2023 financial results conference call.

South koreaVince angottiThomas yipLaurence busseDavid boldtPam palmerJames molloyRaffi asadorianEd arceEmory university school of medicineExchange commissionUniversity of pittsburgh medical centerDepartment of defense or doDepartment of defenseAcelrx pharmaceuticals incAlliance global partners

Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Viking Therapeutics (VKTX) and Assembly Biosciences (ASMB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Universal Health (UHS – Research Report), Vik.

Joseph pantginisEd arceJason cassorlaBioline rx ltd sponsoredTenet healthcareMadrigal pharmaceuticalsActinium pharmaceuticalsAurinia pharmaceuticalsAssembly biosciencesClover health investmentsCommunity healthUniversal healthResearch reportViking therapeuticsGenenta science spa sponsoredStrong buy

Positive Prospects for Inventiva: Pivotal NATiV3 Trial Progress, Anticipated LEGEND Study Results, and Expansion into Asian Markets

In a report released today, Ed Arce from H.C. Wainwright maintained Inventiva (IVA – Research Report) to a Buy, with a price target of $36.

South koreaHepalys pharmaEd arceResearch reportKen cusiArcturus therapeuticsCidara therapeuticsTipranks premium

Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday - Costco Wholesale (NASDAQ:COST), Danaher (NYSE:DHR)

Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market trading.

Corinne jenkinsKen zerbePuneet gargEmmanuel rosnerPaul knightEd arceKen gawrelskiBobby griffinVikram bagriRaymond jamesDeutsche bankTesla incCostco wholesale corporationRoivant sciences ltdMorgan stanleyGoldman sachs

Positive Prospects for Akebia Therapeutics: Buy Rating Upheld Amidst Drug Approval & Global Launch Preparations

Akebia Therapeutics (AKBA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce.

Ed arceTakeda pharmaceuticalsAkebia therapeuticsResearch reportWall streetNew drug applicationGraham rayVice presidentKey accountsTipranks premium

vimarsana © 2020. All Rights Reserved.